Daré Bioscience, Inc.
$2.87
▼
-8.42%
2026-04-21 06:22:00
darebioscience.com
NCM: DARE
Explore Daré Bioscience, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$41.79 M
Current Price
$2.87
52W High / Low
$9.19 / $1.27
Stock P/E
—
Book Value
$0.2
Dividend Yield
—
ROCE
-154.2%
ROE
845.53%
Face Value
—
EPS
$-1.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
0.9
Debt / Equity
93.44
Current Ratio
1.14
Quick Ratio
1.14
Forward P/E
3.13
Price / Sales
25.86
Enterprise Value
$4.59 M
EV / EBITDA
-0.39
EV / Revenue
4.45
Rating
Strong Buy
Target Price
$9.67
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Viridian Therapeutics, Inc. | $14.68 | — | $1.5 B | — | -43.85% | -49.16% | $34.29 / $11.76 | $5.79 |
| 2. | Dianthus Therapeutics, Inc. | $91.92 | — | $5 B | — | -35.57% | -38.38% | $96.5 / $16.64 | $11.41 |
| 3. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 4. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
| 5. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 6. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
| 7. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.02 M | 0 M | -0.02 M | 0.03 M | -0.06 M | — |
| Operating Profit | -1.47 M | -3.67 M | -3.83 M | -4.58 M | -5.39 M | — |
| Net Profit | -1.44 M | -3.56 M | -4.02 M | -4.38 M | -5.51 M | — |
| EPS in Rs | -0.1 | -0.24 | -0.28 | -0.3 | -0.38 | -0.55 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.03 M | 0.01 M | 2.81 M | 10 M |
| Operating Profit | -13.55 M | -23.45 M | -30.94 M | -31.39 M |
| Net Profit | -13.4 M | -4.05 M | -30.16 M | -30.95 M |
| EPS in Rs | -0.92 | -0.28 | -2.07 | -2.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 32.47 M | 22.1 M | 21.28 M | 43.83 M |
| Total Liabilities | 29.63 M | 28.11 M | 26.33 M | 32.71 M |
| Equity | 2.84 M | -6.01 M | -5.05 M | 11.11 M |
| Current Assets | 27.06 M | 18.45 M | 17.54 M | 43.04 M |
| Current Liabilities | 23.69 M | 21.61 M | 20.48 M | 31.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.89 M | 5.47 M | -38.86 M | -18.09 M |
| Investing CF | -0.39 M | -0.57 M | -0.63 M | -0.06 M |
| Financing CF | 19.28 M | 0.35 M | 15.64 M | 1.34 M |
| Free CF | -10.27 M | 4.9 M | -39.49 M | -18.15 M |
| Capex | -0.39 M | -0.57 M | -0.63 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -99.65% | -71.92% | — | — |
| Earnings Growth % | 86.56% | 2.54% | — | — |
| Profit Margin % | -41430.9% | -1074.17% | -309.48% | — |
| Operating Margin % | -239692.2% | -1101.89% | -313.85% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -239259.61% | -1100.53% | -313.61% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-07-01 | 1:0.0833333 |